This research is Trending!
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Key result
Semaglutide 2.4 mg improves symptoms, exercise function, and weight loss versus placebo in HFpEF.
Why the study?
Does semaglutide (2.4 mg) improve symptoms, physical limitations, exercise function, and weight loss in patients with heart failure with preserved ejection fraction and obesity?
Population
Patients with heart failure with preserved ejection fraction and obesity
Comparison
Semaglutide (2.4 mg) vs placebo
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Just for a matter of perspective, [if] people who have a KCCQ-CSS improvement of 15 points or greater, it's a truly transformational change in their symptoms and physical limitations.”
MVMuthiah VaduganathanCardiologist, Brigham and Women's Hospital
“Collectively, these findings signify an initial paradigm-shifting step toward positioning semaglutide, and possibly other emerging incretin-based therapeutics and weight/metabolism-oriented approaches at the center of obesity-related HFpEF management strategies.”
“The higher BMI, increased hsCRP, lower KCCQ scores, and shorter 6MWD at baseline emphasize excess adiposity, inflammation, symptoms and functional limitations, and reduced exercise function as especially important (but historically overlooked) therapeutic targets.”
Implication
Supports semaglutide for symptom relief and weight loss in obese HFpEF; extends prior obesity-trial benefits to this population.
Key Points
- To determine the effects of semaglutide on symptoms, exercise function, and weight in heart failure patients with preserved ejection fraction and obesity.
- Double-blind clinical trial comparing semaglutide to placebo.
- Patients diagnosed with heart failure and obesity were enrolled.
- Semaglutide dosing was set at 2.4 mg.
- Semaglutide led to larger reductions in symptoms and physical limitations compared to placebo.
- Significant improvements in exercise function were observed in the semaglutide group.
- Patients receiving semaglutide experienced greater weight loss than those on placebo.
Structured PICO
Does semaglutide (2.4 mg) improve symptoms, physical limitations, exercise function, and weight loss in patients with heart failure with preserved ejection fraction and obesity?
P
Population
Patients with heart failure with preserved ejection fraction and obesity
I
Intervention
Semaglutide (2.4 mg)
C
Comparator
Placebo
O
Outcome
Reductions in symptoms and physical limitations, improvements in exercise function, and weight losspatient reported
In patients with HFpEF and obesity, semaglutide 2.4 mg significantly improves heart failure symptoms, physical limitations, and exercise function while promoting weight loss.
Cite This Study
Kosiborod et al. (2023) studied this question. Semaglutide (2.4 mg) significantly improved symptoms, physical limitations, exercise function, and caused greater weight loss compared to placebo in heart failure patients with preserved ejection frac.